BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Press Releases

  Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

  July 29, 2024

   · 

  5 min read
• Business

  WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

  July 29, 2024

   · 

  1 min read
• Press Releases

  Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement

  July 29, 2024

   · 

  5 min read
• Press Releases

  Alzheimer’s Disease Blood Tests Could Improve Diagnosis in Primary Care, Speed Recruiting for Research & Reduce Wait Times

  July 29, 2024

   · 

  10 min read
• Press Releases

  Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

  July 29, 2024

   · 

  8 min read
• Press Releases

  Regeneration Biomedical to Present Data on First Two Subjects in a Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brains of Patients with Alzheimer’s Disease

  July 29, 2024

   · 

  3 min read
• Press Releases

  Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

  July 29, 2024

   · 

  12 min read
• Press Releases

  CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy

  July 29, 2024

   · 

  15 min read
• Press Releases

  Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

  July 29, 2024

   · 

  8 min read
• Press Releases

  vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

  July 29, 2024

   · 

  3 min read